Monopar Therapeutics (MNPR) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 81.3% versus a loss of 14.8%. Over five years, MNPR leads with a +242.1% price change compared with -55.0% for SLN. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($591.7 million vs $563.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | SLN |
|---|---|---|
| Share price | $83.98 | $9.52 |
| Market cap | $563.69M | $591.71M |
| 1-day change | +0.24% | -3.05% |
| YTD return | +28.61% | +56.58% |
| 1-year return | -14.80% | +81.33% |
| 5-year return | +242.08% | -55.00% |
| EPS (TTM) | $-2.20 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $17.58 |
| 52-week low | $50.07 | $4.19 |
| Distance from 52-week high | -32.72% | -45.84% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +54.70% | +246.64% |
| Average volume | 215.52K | 1.12M |
| Shares outstanding | 6.71M | 62.15M |
| Employees | 22 | 88 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed MNPR by 96.1 percentage points over the past year.
- The two companies sit in different sectors: Monopar Therapeutics in Health Care and Silence Therapeutics Plc American Depository Share in Healthcare.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Healthcare · Biotechnology · 88 employees
MNPR vs SLN FAQ
Which is bigger, Monopar Therapeutics or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $591.71M compared with $563.69M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, MNPR or SLN?
SLN returned +81.33% over the past 12 months, compared with -14.80% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Silence Therapeutics Plc American Depository Share in the same industry?
No. Monopar Therapeutics is in the Health Care sector, while Silence Therapeutics Plc American Depository Share is in Healthcare.